Telemedicine in the Era of COVID-19: Mitigating Risk for People Living with Multiple Sclerosis

Released On
July 31, 2020

Expires On
July 31, 2021

Media Type
Internet

Completion Time
90 minutes

Specialty
Neurology, Primary Care, Pharmacy

Topic(s)
Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This CME/CE activity is jointly provided by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

 

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours
  • Pharmacists - 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for neurology and primary care physicians, nurse practitioners, PAs, nurses, pharmacists, rehabilitation specialists, mental health professionals, and other members of the healthcare team essential to the care of patients living with MS.

Learning Objectives

 

  • Review the history of and current known facts related to COVID-19
  • Describe the risks of COVID-19 in people living with MS
  • Discuss opportunities for care and best practices for implementation of telemedicine for people living with MS
  • Employ best practices for implementation of telemedicine in MS management

Faculty

Edward J. Fox, MD, PhD (Chairperson)

Director, MS Clinic of Central Texas
Central Texas Neurology Consultants, PA
Clinical Associate Professor, University of Texas Dell Medical School

Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN

Director of Clinical Services
Multiple Sclerosis Clinic of Central Texas

Joseph R. Berger, MD, FACP, FAAN, FANA

Professor of Neurology and Associate Chief of the MS Division
Perelman School of Medicine
University of Pennsylvania

Frederick W. Foley, PhD

Professor of Psychology, Yeshiva University, Ferkauf Graduate School of Psychology
Director of Neuropsychology and Psychosocial Research, Holy Name Medical Center Multiple Sclerosis Center

Continuing Medical Education

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physician Credit Designation

The CMSC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

The CMSC designates this activity for a maximum of 1.5 contact hours of continuing nursing education (0.5 in the area of pharmacology).

Pharmacists

This knowledge-based activity, JA4008165-9999-20-038-H01-P , qualifies for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit.

Disclosures of Conflicts of Interest

It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

The following faculty report that they have relevant financial relationships to disclose:

Edward J. Fox, MD, PhD

  • Consulting fees: Alexion, Biogen, Bristol-Myers Squibb, EMD Serono, Genentech Roche, Novartis
  • Speakers bureau: Alexion, Biogen, Bristol-Myers Squibb, EMD Serono, Genentech Roche, Sanofi Genzyme
  • Contracted research: Biogen, Bristol-Myers Squibb, Chugai, EMD Serono, Genentech Roche, MedDay, Novartis, Sanofi Genzyme, TG Therapeutics

Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN

  • Consulting fees: Biogen, Bristol-Myers Squibb, EMD Serono, Genentech, Roche, Novartis, Viela Bio
  • Speakers bureau: Biogen, Bristol-Myers Squibb, EMD Serono, Genentech, Roche, Novartis, Viela Bio

Joseph R. Berger, MD, FACP, FAAN, FANA

  • Consulting fees: Biogen, Celgene, Excision, Genentech/Roche, Genzyme, Millennium/Takeda, Novartis, Inhibikase Therapeutics
  • Contracted research: Biogen, Genentech/Roche

Frederick W. Foley, PhD, has declared that he has no relevant financial relationships to disclose.

Activity Staff Disclosures

June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.

All other planners, reviewers, and staff at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Method of Participation

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive credit, participants must read the CME/CE information and faculty disclosures, complete the pre-test questions, view the activity, and complete the post-test and evaluation form. Statements of Credit are awarded upon successful completion of the post-test, with a passing score of 100%, and evaluation form.

Certificates will be emailed to the participant.

For information about this program, please contact Catamount Medical Education at: info@catmeded.com.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For CE questions, please contact: Catamount Medical Education at: info@catmeded.com